Skip to main content
Fig. 6 | Genome Biology

Fig. 6

From: ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism

Fig. 6

ADAR1 silencing sensitizes glioblastoma cells to TMZ treatment and inhibits glioblastoma growth in vivo. a shADAR1 U87MG cells were treated with or without 100 μM TMZ. Apoptotic cells were evaluated (Annexin V staining) 24–72 h post TMZ treatment. Values are represented as means ± SD, *p ≤ 0.05; **p ≤ 0.01. b An example of two similar experiments showing the difference of tumor mass (after 2 months) generated from shADAR1 and shscr U87MG cells subcutaneously injected into the flack of nude mice (n = 4 mice). c shADAR1 and shscr U87MG cells were injected intracranially (n = 6); a representative section (H&E staining) and tumor volume are shown, p = 0.0202 (Mann-Whitney t-test). d Left, representative section showing the Ki67 staining in brain tumors obtained in shADAR1 and shcsr U87MG cells. The tumor mass (T) and normal brain (N) are indicated. Right, Ki67 expression in the same tumors, p = 0.0286 (Mann-Whitney t-test). e Left, representative sections showing ADAR1 staining in brain tumors obtained with shADAR1 and shcsr U87MG cells. Right, ADAR1 expression in the same tumors, p = 0.0043 (Mann-Whitney t-test)

Back to article page